FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3132302006> ?p ?o ?g. }

• W3132302006 endingPage "341" @default.
• W3132302006 startingPage "328" @default.
• W3132302006 abstract "Positive allosteric modulation of metabotropic glutamate subtype 5 (mGlu₅) receptor has emerged as a potential new therapeutic strategy for the treatment of schizophrenia and cognitive impairments. However, positive allosteric modulator (PAM) agonist activity has been associated with adverse side effects, and neurotoxicity has also been observed for pure PAMs. The structural and pharmacological basis of therapeutic versus adverse mGlu₅ PAM in vivo effects remains unknown. Thus, gaining insights into the signaling fingerprints, as well as the binding kinetics of structurally diverse mGlu₅ PAMs, may help in the rational design of compounds with desired properties. We assessed the binding and signaling profiles of <i>N</i>-methyl-5-(phenylethynyl)pyrimidin-2-amine (MPPA), 3-cyano-<i>N</i>-(2,5-diphenylpyrazol-3-yl)benzamide (CDPPB), and 1-[4-(4-chloro-2-fluoro-phenyl)piperazin-1-yl]-2-(4-pyridylmethoxy)ethenone [compound 2c, a close analog of 1-(4-(2-chloro-4-fluorophenyl)piperazin-1-yl)-2-(pyridin-4-ylmethoxy)ethanone] in human embryonic kidney 293A cells stably expressing mGlu₅ using Ca²⁺ mobilization, inositol monophosphate (IP₁) accumulation, extracellular signal–regulated kinase 1/2 (ERK1/2) phosphorylation, and receptor internalization assays. Of the three allosteric ligands, only CDPPB had intrinsic agonist efficacy, and it also had the longest receptor residence time and highest affinity. MPPA was a biased PAM, showing higher positive cooperativity with orthosteric agonists in ERK1/2 phosphorylation and Ca²⁺ mobilization over IP₁ accumulation and receptor internalization. In primary cortical neurons, all three PAMs showed stronger positive cooperativity with (<i>S</i>)-3,5-dihydroxyphenylglycine (DHPG) in Ca²⁺ mobilization over IP₁ accumulation. Our characterization of three structurally diverse mGlu₅ PAMs provides further molecular pharmacological insights and presents the first assessment of PAM-mediated mGlu₅ internalization. <h3>SIGNIFICANCE STATEMENT</h3> Enhancing metabotropic glutamate receptor subtype 5 (mGlu₅) activity is a promising strategy to treat cognitive and positive symptoms in schizophrenia. It is increasingly evident that positive allosteric modulators (PAMs) of mGlu₅ are not all equal in preclinical models; there remains a need to better understand the molecular pharmacological properties of mGlu₅ PAMs. This study reports detailed characterization of the binding and functional pharmacological properties of mGlu₅ PAMs and is the first study of the effects of mGlu₅ PAMs on receptor internalization." @default.
• W3132302006 created "2021-03-01" @default.
• W3132302006 creator A5019565246 @default.
• W3132302006 creator A5037199675 @default.
• W3132302006 creator A5046533529 @default.
• W3132302006 creator A5047477513 @default.
• W3132302006 creator A5070639742 @default.
• W3132302006 creator A5073357827 @default.
• W3132302006 creator A5089455458 @default.
• W3132302006 creator A5091568150 @default.
• W3132302006 date "2021-02-18" @default.
• W3132302006 modified "2023-10-10" @default.
• W3132302006 title "Positive Allosteric Modulators of Metabotropic Glutamate Receptor 5 as Tool Compounds to Study Signaling Bias" @default.
• W3132302006 cites W1483576392 @default.
• W3132302006 cites W1501203786 @default.
• W3132302006 cites W1867617310 @default.
• W3132302006 cites W1965132832 @default.
• W3132302006 cites W1966912675 @default.
• W3132302006 cites W1967627800 @default.
• W3132302006 cites W1971280927 @default.
• W3132302006 cites W1986637168 @default.
• W3132302006 cites W1987856394 @default.
• W3132302006 cites W1995919912 @default.
• W3132302006 cites W2001484994 @default.
• W3132302006 cites W2006803138 @default.
• W3132302006 cites W2007635892 @default.
• W3132302006 cites W2014213356 @default.
• W3132302006 cites W2019933465 @default.
• W3132302006 cites W2029542833 @default.
• W3132302006 cites W2030718808 @default.
• W3132302006 cites W2031195859 @default.
• W3132302006 cites W2033160727 @default.
• W3132302006 cites W2041536389 @default.
• W3132302006 cites W2047935630 @default.
• W3132302006 cites W2069715167 @default.
• W3132302006 cites W2074631079 @default.
• W3132302006 cites W2094911003 @default.
• W3132302006 cites W2099576957 @default.
• W3132302006 cites W2101896923 @default.
• W3132302006 cites W2104065746 @default.
• W3132302006 cites W2110319068 @default.
• W3132302006 cites W2125775392 @default.
• W3132302006 cites W2132940855 @default.
• W3132302006 cites W2137464199 @default.
• W3132302006 cites W2149141089 @default.
• W3132302006 cites W2154092739 @default.
• W3132302006 cites W2154437375 @default.
• W3132302006 cites W2161998279 @default.
• W3132302006 cites W2171826008 @default.
• W3132302006 cites W2186153196 @default.
• W3132302006 cites W2207535250 @default.
• W3132302006 cites W2288077045 @default.
• W3132302006 cites W2464433465 @default.
• W3132302006 cites W2559740524 @default.
• W3132302006 cites W2611100790 @default.
• W3132302006 cites W2735354780 @default.
• W3132302006 cites W2746860912 @default.
• W3132302006 cites W2764274634 @default.
• W3132302006 cites W2782408527 @default.
• W3132302006 cites W2788583047 @default.
• W3132302006 cites W2794090722 @default.
• W3132302006 cites W2899026785 @default.
• W3132302006 cites W2913510060 @default.
• W3132302006 cites W2963558305 @default.
• W3132302006 cites W2965966449 @default.
• W3132302006 cites W2981263508 @default.
• W3132302006 cites W2983575094 @default.
• W3132302006 cites W3021285464 @default.
• W3132302006 cites W3023393557 @default.
• W3132302006 cites W3023567963 @default.
• W3132302006 cites W3113792226 @default.
• W3132302006 doi "https://doi.org/10.1124/molpharm.120.000185" @default.
• W3132302006 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33602724" @default.
• W3132302006 hasPublicationYear "2021" @default.
• W3132302006 type Work @default.
• W3132302006 sameAs 3132302006 @default.
• W3132302006 citedByCount "4" @default.
• W3132302006 countsByYear W31323020062021 @default.
• W3132302006 countsByYear W31323020062022 @default.
• W3132302006 countsByYear W31323020062023 @default.
• W3132302006 crossrefType "journal-article" @default.
• W3132302006 hasAuthorship W3132302006A5019565246 @default.
• W3132302006 hasAuthorship W3132302006A5037199675 @default.
• W3132302006 hasAuthorship W3132302006A5046533529 @default.
• W3132302006 hasAuthorship W3132302006A5047477513 @default.
• W3132302006 hasAuthorship W3132302006A5070639742 @default.
• W3132302006 hasAuthorship W3132302006A5073357827 @default.
• W3132302006 hasAuthorship W3132302006A5089455458 @default.
• W3132302006 hasAuthorship W3132302006A5091568150 @default.
• W3132302006 hasBestOaLocation W31323020061 @default.
• W3132302006 hasConcept C119128870 @default.
• W3132302006 hasConcept C166342909 @default.
• W3132302006 hasConcept C170493617 @default.
• W3132302006 hasConcept C185592680 @default.
• W3132302006 hasConcept C200385062 @default.
• W3132302006 hasConcept C2776038425 @default.
• W3132302006 hasConcept C2778938600 @default.
• W3132302006 hasConcept C41653306 @default.

• next